Drug profile

The FDA adverse-event record for Trimeprazine/Prednisolone

58 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Trimeprazine/Prednisolone. See the species affected, top reactions, and outcomes below.

58
adverse-event reports
10.3%
death-coded share
Dog
most-reported species
14
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
58
Total Reports
6
Deaths Reported
10.3%
Death Rate

Active Ingredients

Trimeprazine/Prednisolone

Administration Routes

OralUnknown

Species Affected

Dog 57
Cat 1

Most Affected Breeds

Retriever - Labrador 5
Retriever - Golden 5
Shih Tzu 3
Pit Bull 3
Crossbred Canine/dog 3
Mixed (Dog) 2
Spaniel - Cocker American 2
Terrier - Jack Russell 2
Spaniel - King Charles Cavalier 2
Terrier - West Highland White 2

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 14
Other abnormal test result NOS 14
Vomiting 13
Diarrhoea 8
Pruritus 7
Anorexia 6
Weight loss 6
Death by euthanasia 6
Behavioural disorder NOS 5
INEFFECTIVE, ATOPY CONTROL 5
Seizure NOS 5
Elevated liver enzymes 4

Outcome Breakdown

Recovered/Normal
25 (42.4%)
Outcome Unknown
19 (32.2%)
Ongoing
8 (13.6%)
Euthanized
6 (10.2%)
Recovered with Sequela
1 (1.7%)

Trimeprazine/Prednisolone Adverse Event Insights

58 reports name Trimeprazine/Prednisolone; 6 recorded a death outcome (10.3% of reported events, not a population-level mortality rate). Active ingredient: Trimeprazine/Prednisolone. Administration routes: Oral, Unknown.

By species: Dog (57 reports), Cat (1 reports). By breed: Retriever - Labrador (5), Retriever - Golden (5), Shih Tzu (3).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (14), Other abnormal test result NOS (14), Vomiting (13), Diarrhoea (8). Outcome, 59 coded reports: Recovered/Normal leads at 42.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.